Marcus W. Bosenberg
Research Subjects
Marcus W. Bosenberg has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Cara Hobbs
Department of Pathology, University of Vermont, Burlington, Vermont
2 shared publications- Cristina Nogueira
Centre for Genomic Regulation, The Barcelona Institute of Science and Technology, 08003 Barcelona, Spain Universitat Pompeu Fabra, 08002 Barcelona, Spain
2 shared publications David P. Curley
E‐mail
2 shared publicationsLynda Chin
Department of Medical Oncology and Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts
2 shared publicationsViswanathan Muthusamy
Department of Pathology, University of Vermont, Burlington, Vermont
2 shared publicationsBetsy Nelson
Department of Pathology, University of Vermont, Burlington, Vermont
1 shared publication
Latest Publications
- 30 October 2007
- Published by Wiley in Pigment Cell & Melanoma Research
- Vol. 21 (1) , 5-6
NEWS AND VIEWS: A new mechanism of release from senescence: suppression of p16INK4a by beta-catenin
- 30 October 2007
- Published by Wiley in Pigment Cell & Melanoma Research
- Vol. 21 (1) , 5-6
NEWS AND VIEWS: A new mechanism of release from senescence: suppression of p16INK4a by beta-catenin
Characterization of melanocyte‐specific inducible Cre recombinase transgenic mice
Conditional Cre‐mediated recombination has emerged as a robust method of introducing somatic genetic alterations in an organ‐specific manner in the mouse. Here, we generated and characterized mice harboring a 4‐hydroxytamoxifen (OHT)‐inducible Cre recombinase‐estrogen receptor fusion transgene under the control of the melanocyte‐specific tyrosinase promoter, designated Tyr::CreERT2. Cre‐mediated recombination was induced in melanocytes in a spatially and temporally controlled manner upon administration of OHT and was documented in embryonic melanoblasts, follicular bulb melanocytes, dermal dendritic melanocytes, epidermal melanocytes of tail skin, and in putative melanocyte stem cells located within the follicular bulge. Functional evidence suggestive of recombination in follicular melanocyte stem cells included the presence of Cre‐mediated recombination in follicular bulb melanocytes 1 year after topical OHT administration, by which time several hair cycles have elapsed and the melanocytes residing in this location have undergone multiple rounds of apoptosis and replenishment. These Tyr:: CreERT2 transgenic mice represent a useful resource for the evaluation of melanocyte developmental genetics, the characterization of melanocyte stem cell function and dynamics, and the construction of refined mouse models of malignant melanoma. genesis 44:262–267, 2006. Published 2006 Wiley‐Liss, Inc.
Characterization of melanocyte‐specific inducible Cre recombinase transgenic mice
Conditional Cre‐mediated recombination has emerged as a robust method of introducing somatic genetic alterations in an organ‐specific manner in the mouse. Here, we generated and characterized mice harboring a 4‐hydroxytamoxifen (OHT)‐inducible Cre recombinase‐estrogen receptor fusion transgene under the control of the melanocyte‐specific tyrosinase promoter, designated Tyr::CreERT2. Cre‐mediated recombination was induced in melanocytes in a spatially and temporally controlled manner upon administration of OHT and was documented in embryonic melanoblasts, follicular bulb melanocytes, dermal dendritic melanocytes, epidermal melanocytes of tail skin, and in putative melanocyte stem cells located within the follicular bulge. Functional evidence suggestive of recombination in follicular melanocyte stem cells included the presence of Cre‐mediated recombination in follicular bulb melanocytes 1 year after topical OHT administration, by which time several hair cycles have elapsed and the melanocytes residing in this location have undergone multiple rounds of apoptosis and replenishment. These Tyr:: CreERT2 transgenic mice represent a useful resource for the evaluation of melanocyte developmental genetics, the characterization of melanocyte stem cell function and dynamics, and the construction of refined mouse models of malignant melanoma. genesis 44:262–267, 2006. Published 2006 Wiley‐Liss, Inc.
- 17 January 2006
- Published by Wiley in Genes, Chromosomes and Cancer
- Vol. 45 (5) , 447-454
Amplification of CDK4 and MDM2 in malignant melanoma
Amplification of the 12q13–15 region is a common event in several human tumors including liposarcomas, gliomas, and osteosarcomas. We have demonstrated high‐level amplification of 12q14 in a subset of uncultured malignant melanomas (3 of 53). High‐resolution mapping of the amplicon using quantitative PCR revealed a bipartite amplicon consisting of a primary 50‐kb amplicon centered on CDK4 and a secondary amplicon centered on MDM2, without amplification of the intervening 11 Mb of genomic DNA. Analysis of mRNA and protein levels in melanomas with 12q14 amplification demonstrated overexpression of target genes CDK4 and MDM2 without loss of CDKN2A‐P16 (P16INK4A) or CDKN2A‐P14ARF (P14ARF) expression, important regulators of the RB1 and TP53 pathways, which are commonly lost or mutated in melanoma. These results suggest that coamplification of CDK4 and MDM2 may substitute for loss of P16INK4A and P14ARF function in a subset of melanomas.
- 17 January 2006
- Published by Wiley in Genes, Chromosomes and Cancer
- Vol. 45 (5) , 447-454
Amplification of CDK4 and MDM2 in malignant melanoma
Amplification of the 12q13–15 region is a common event in several human tumors including liposarcomas, gliomas, and osteosarcomas. We have demonstrated high‐level amplification of 12q14 in a subset of uncultured malignant melanomas (3 of 53). High‐resolution mapping of the amplicon using quantitative PCR revealed a bipartite amplicon consisting of a primary 50‐kb amplicon centered on CDK4 and a secondary amplicon centered on MDM2, without amplification of the intervening 11 Mb of genomic DNA. Analysis of mRNA and protein levels in melanomas with 12q14 amplification demonstrated overexpression of target genes CDK4 and MDM2 without loss of CDKN2A‐P16 (P16INK4A) or CDKN2A‐P14ARF (P14ARF) expression, important regulators of the RB1 and TP53 pathways, which are commonly lost or mutated in melanoma. These results suggest that coamplification of CDK4 and MDM2 may substitute for loss of P16INK4A and P14ARF function in a subset of melanomas.